Alliance targets CNS imaging
E-Clinical solutions provider Perceptive Informatics says it has joined with Biospective to enhance its capabilities for processing and analysis of medical images for central nervous system (CNS) and oncology related clinical trials. Perceptive will use Biospective's specialized medical imaging process and analysis software to supplement its existing technology in support of independent reviews of imaging data for both exploratory and large-scale, multi-center studies, according to an announcement.
Perceptive's intent is to help clients use medical imaging as an endpoint, or biomarker, to assess efficacy and safety of drug candidates, the announcement says. Biospective will provide software solutions tailored for CNS and oncology studies, including specialized Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) techniques.
Bioluminescent imaging studies have recently played a major role in research at the New York University School of Medicine into a form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). A study in the June 18, 2009, issue of Nature details the molecular agents behind the disease, which infiltrates the central nervous system.